N. A. Mironova

Learn More
Currently, the main way to fight cancer is still chemotherapy. This method of treatment is at the height of its capacity, so, setting aside the need for further improvements in traditional treatments for neoplasia, it is vital to develop now approaches toward treating malignant tumors. This paper reviews innovational experimental approaches to treating(More)
In our work the antitumor and antimetastatic activities of RNase A and DNase I were studied using two murine models of pulmonary (Lewis lung carcinoma) and liver (hepatoma A-1) metastases. We found that intramuscular administration of RNase A at the dose range of 0.1-50 µ g/kg retarded the primary tumor growth by 20-40%, and this effect disappeared with the(More)
Fragments corresponding to the 83–98 sequence of the first extracellular loop and to the 168–192 and 171–182 sequences of the second extracellular loop of the M2-muscarinic receptor (antibodies to this receptor could be markers of early symptoms of heart disorders) were synthesized by solid phase method using the Fmoc-SPPS strategy. A new conformational(More)
By the means of computer simulation, the polypeptide antigen conformational structure that initiates the immunodominant epitope of the 2nd extracellular loop of β1-adrenoreceptor has been built. A linear 25-member peptide corresponding to the calculated sequence was synthesized by means of the solid-phase method using Fmoc-technology, then by means of the(More)
Changes in the activity of β2-adrenergic receptors of human T-lymphocytes under the effect of salbutamol (a short-acting β2-agonist) have been evaluated with a new modified radioligand method utilizing [125I]cyanopindolol and a specific ligand ICI 118551. In healthy volunteers, the receptor activity decreased after 30 min upon the inhalation of salbutamol(More)
  • 1